ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at RBC Global Healthcare Conference Transcript

May 19, 2020 / 05:55PM GMT
Release Date Price: $51.04 (-1.96%)
Gregory James Renza
RBC Capital Markets, Research Division - Analyst

Thank you, everybody, for joining us again today. My name is Greg Renza, one of the RBC Capital Market's technology equity research analyst. And we are joined now by ACADIA Pharmaceuticals. Very excited to have the team here today. And with us is Steve Davis; Chief Executive Officer; Dr. Serge Stankovic, President; and Elena Ridloff, Executive Vice President and Chief Financial Officer.

Team, thank you very much, and we look forward to talking about the ACADIA story.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Thank you, Greg.

Gregory James Renza;Stephen R. Davis
RBC Capital Markets, Research Division - Analyst

Steve, maybe the best way for us -- great. Maybe the best way for us to start is just to allow you the opportunity to give a brief introduction of the company, what your latest thinking is on the key 3 strategic pillars of ACADIA and how that has essentially evolved over time?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot